Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinjikang No. 1 (心肌康1号) is a traditional Chinese medicine formulation primarily used for cardiovascular indications, especially for viral myocarditis and related symptoms such as palpitations, shortness of breath, chest tightness or pain, fatigue, insomnia, and other manifestations associated with qi-yin deficiency and blood stasis-heat syndrome. The product is described as having functions to tonify qi and nourish yin while promoting blood circulation and detoxification. It is typically administered in the form of granules[3]. The mechanism of action involves improving myocardial nutrition blood flow, reducing myocardial oxygen consumption, enhancing anti-hypoxia capacity, protecting against myocardial ischemia injury, expanding coronary vessels to increase coronary blood flow volume[3]. This drug is developed based on principles of traditional Chinese medicine rather than a single molecular target; its active ingredients are derived from herbal sources (specific composition may vary by manufacturer).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xinjikang no. 1.